News - Sandoz

Filter

Current filters:

Sandoz

Popular Filters

26 to 50 of 50 results

US FTC puts divestment conditions on Watson's acquisition of Actavis

16-10-2012

The USA's Federal Trade Commission will require Watson Pharmaceuticals (NYSE: WPI) and fellow generic…

ActavisGenericsLegalMergers & AcquisitionsNorth AmericaNovartisPar PharmaceuticalsSandozWatson Pharmaceuticals

"Sandoz will be the leading biosimilars company in 2012," says Visiongain

04-10-2012

Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global…

BiotechnologyDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingNovartisSandoz

Novartis beats forecasts, despite generic and currency hits

19-07-2012

Second-quarter 2012 group net sales at Swiss drug major Novartis (NOVN: VX) came in at of $14.3 billion,…

AlconFinancialGenericsNovartisPharmaceuticalSandoz

Alabama Supreme Court ruling favors Sandoz in Medicaid pricing case

16-07-2012

The USA's Alabama Supreme Court came out in favor of Sandoz, the generics subsidiary of Swiss drug major…

GenericsLegalNorth AmericaNovartisPricingSandoz

Biosimilars can save eight EU countries up to 33 billion euros on health care by 2020

16-05-2012

By 2020, eight countries in the European Union could save a cumulative total of between 11.8 billion…

BiotechnologyEuropeGenericsHealthcareNovartisPricingSandoz

Sandoz to emphasize need for consistent regulatory standards across all biologics at FDA hearings

10-05-2012

Germany-based Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX) announced that Mark McCamish,…

BiotechnologyGeneralNorth AmericaNovartisRegulationResearchSandoz

Novartis to buy US generic derma company Fougera for over $1.5 billion

03-05-2012

Further expanding its generic drug foot print, Swiss drug giant Novartis (NOVN: VX) is adding to its…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNovartisPharmaceuticalSandoz

Cancer drugs shortages persist in Poland

26-04-2012

In Poland, the recent procurement problems of cancer drugs is far from solved, writes Sebastian Gensior…

EuropeGenericsHealthcareNovartisOncologyPharmaceuticalPricingSandoz

Sandoz links with Cinpharm for generics in Sub-Saharan Africa

24-04-2012

Sandoz, the generics business of Swiss drug major Novartis (NOVN: VX), said yesterday that its German…

CinpharmGenericsMarkets & MarketingNovartisRest of the WorldSandoz

Novartis expands transplant portfolio with first branded generic tacrolimus

04-04-2012

Swiss drug major Novartis has announced the US introduction and availability of Hecoria (tacrolimus)…

Astellas PharmaGenericsHecoriaImmunologicalsMarkets & MarketingNorth AmericaNovartisPrografSandoztacrolimus

United Therapeutics sues Sandoz over Remodulin patent infringement

16-03-2012

United Therapeutics (Nasdaq: UTHR) says that it has filed a law suit in the US District Court for the…

Cardio-vascularGenericsLegalNorth AmericaNovartisPatentsPharmaceuticalRemodulinSandozUnited Therapeutics

Apricus collaborates with Sandoz for ED drug

17-02-2012

San Diego, USA-based Apricus Biosciences (Nasdaq: APRI) said yesterday that its wholly-owned subsidiary…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalReproductiveSandozVitaros

Sandoz challenges United Thera’s Remodulin patents

06-02-2012

US drugmaker United Therapeutics (Nasdaq: UTHR) says that it has received a Paragraph IV Certification…

GenericsNorth AmericaNovartisPatentsPharmaceuticalRegulationRemodulinRespiratory and PulmonarySandozUnited Therapeutics

Novartis financials in line with expectations

25-01-2012

Swiss drug major Novartis (NOVN: VX) posted fourth quarter and full-year 2011 financial results this…

FinancialNovartisPharmaceuticalSandoz

Sandoz initiates two more Phase III biosimilar trials

20-01-2012

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), says that it has initiated two milestone…

AmgenBiotechnologyFilgrastimGenericsNovartisOncologypegfilgrastimResearchSandozZarzio

Sandoz expands strategic alliance with Nipro in Japan; Shionogi licenses drug to Ildong

14-07-2011

Sandoz, a generics subsidiary of US drug major Novartis (NOVN: VX) has entered into a strategic alliance…

Asia-PacificGenericsIldong PharmaLicensingNovartisPharmaceuticalpirfenidoneSandozShionogi

Shire sues Sandoz and Amneal for Vyvanse patent infringements

05-07-2011

Ireland-headquartered drugmaker Shire (LSE: SHP) says it has filed law suits in the US District Court…

Amneal PharmaGenericsLegalNeurologicalNorth AmericaNovartisPatentsPharmaceuticalSandozShireVyvanse

Sandoz files for generic of Shire’s Vyvanse; FDA warning

20-05-2011

Ireland-headquartered biopharmaceutical company Shire (LSE: SHP) yesterday revealed that its US subsidiary…

GenericsMarkets & MarketingNeurologicalNorth AmericaNovartisPatentsPharmaceuticalRegulationSandozShireVyvanse

26 to 50 of 50 results

Back to top